Susanne Saussele, MD, University of Heidelberg, Germany, recommends monitoring patients closely after discontinuing treatment in case they experience a rapid rise in BCR-ABL levels. In patients experiencing severe side effects from TKI use who have been in MR4 for a long time, Dr Saussele recommends discontinuing treatment and monitoring BCR-ABL levels.